Company news
Scynexis, Inc. (NASDAQ:SCYX) news
Every Scynexis, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
SCYNEXIS to Participate in Upcoming Investor Conferences
September 1, 2026
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (AD...
June 30, 2026
SCYNEXIS Announces One-for-Eight Reverse Stock Split
May 22, 2026
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 11, 2026
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
March 31, 2026
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Aut...
March 31, 2026
SCYNEXIS Announces $40.0 Million Private Placement
March 31, 2026
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
March 4, 2026
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
February 26, 2026
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
February 17, 2026
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resis...
January 28, 2026
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
January 21, 2026
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
December 22, 2025
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
November 19, 2025
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeu...
November 17, 2025
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 5, 2025
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
October 15, 2025
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fung...
September 30, 2025
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends i...
September 4, 2025
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
August 25, 2025
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
May 28, 2025
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and In...
April 8, 2025
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
March 12, 2025
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
December 18, 2024
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2024
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
October 10, 2024
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
October 3, 2024
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 8, 2024
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
July 23, 2024
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology...
April 30, 2024
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infe...
April 9, 2024
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
January 30, 2024
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis ...
January 29, 2024
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Con...
January 5, 2024
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
October 24, 2023
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) Octob...
October 16, 2023
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-...
September 27, 2023
SCYNEXIS to Participate in September Investor Conferences
August 28, 2023
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
July 20, 2023
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
June 21, 2023